Testing whether lowering UDCA helps people with PBC
Treatments studied
Part of Digestive system clinical trials.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with primary biliary cholangitis (PBC).
- Your liver disease stage is 2 or 3 (you may have abnormal liver tests and symptoms).
- After 6–12 months on UDCA, your ALP and AST are improved (both at or below 1.5× the lab’s upper normal limit) and your bilirubin is normal.
- You must not have other overlapping liver diseases (like hepatitis B or C or alcohol-related liver disease), and your ALT/AST must not be more than 2× normal.
- You should not have advanced liver weakening (Child B or C), major organ problems, serious infection, or pregnancy/breastfeeding, and you can’t join if you’re in another study (or joined one in the last 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This study tests a new treatment using stem cells from umbilical cord blood to help people with primary biliary cholangitis (PBC) who haven't gotten better with standard medication. It aims to improve liver function and reduce symptoms.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.